Kalaris Therapeutics (KLRS) Stock Price, News & Analysis

Company Overview

Kalaris Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for retinal vascular diseases. The company’s work is aimed at addressing conditions in which abnormal blood-vessel growth or leakage can impair vision.

Kalaris Therapeutics’ lead investigational product is KAL-001, an ophthalmic biologic being developed for retinal diseases, including conditions such as diabetic macular edema and neovascular age-related macular degeneration. The company’s pipeline remains under clinical development, and its products have not been established as safe or effective for commercial use.

The company is headquartered in the United States and is focused primarily on advancing its retinal-disease research and clinical programs. Publicly available information about its broader commercial operations and leadership is limited.

Key Stats

• Today's Range: $2.36 to $2.55
• 50-Day Range: $2.36 to $4.32
• 52-Week Range: $2.35 to $11.88
• Volume: 104,425 shs
• Average Volume: 84,143 shs
• Market Capitalization: $56.19 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.75
• Consensus Rating: Moderate Buy

Kalaris Therapeutics Stock Analysis - MarketRank™

Kalaris Therapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 661st out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Kalaris Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Kalaris Therapeutics has a consensus price target of $18.75, representing about 694.5% upside from its current price of $2.36.

Amount of Analyst Coverage

Kalaris Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Earnings Growth

Earnings for Kalaris Therapeutics are expected to remain at ($1.99) per share in the coming year.

Price to Earnings Ratio vs. the Market

The P/E ratio of Kalaris Therapeutics is -1.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kalaris Therapeutics is -1.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Kalaris Therapeutics has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.37% of the float of Kalaris Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Kalaris Therapeutics has a short interest ratio ("days to cover") of 4.56.

Change versus previous month

Short interest in Kalaris Therapeutics has recently increased by 4.25%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kalaris Therapeutics does not currently pay a dividend.

Dividend Growth

Kalaris Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: N/A

News Sentiment

Kalaris Therapeutics has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Kalaris Therapeutics this week, compared to 2 articles on an average week.

MarketBeat Follows

2 people have added Kalaris Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kalaris Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

68.10% of the stock of Kalaris Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

66.05% of the stock of Kalaris Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:KLRS
• CIK: 1754068
• Web: www.kalaristx.com
• Phone: (650) 249-2727
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Kalaris Therapeutics: $18.75
• High Price Target: $25.00
• Low Price Target: $14.00
• Potential Upside/Downside: +694.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$43.44 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -71.71%
• Return on Assets: -42.95%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.98
• Quick Ratio: 10.98

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.21 per share
• Price / Book: 0.56

Miscellaneous

• Outstanding Shares: 23,810,000
• Free Float: 7,594,000
• Market Cap: $56.19 million
• Optionable: N/A
• Beta: 0.42